RAPT Therapeutics, Inc.·4

Nov 15, 8:00 PM ET

Young Rodney KB 4

4 · RAPT Therapeutics, Inc. · Filed Nov 15, 2024

Insider Transaction Report

Form 4
Period: 2024-11-13
Young Rodney KB
CHIEF FINANCIAL OFFICER
Transactions
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-11-13140,0000 total
    Exercise: $21.73Exp: 2029-12-01Common Stock (140,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2024-11-13+140,000140,000 total
    Exercise: $1.57Exp: 2029-12-01Common Stock (140,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-11-1360,0000 total
    Exercise: $19.53Exp: 2031-01-27Common Stock (60,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2024-11-13+60,00060,000 total
    Exercise: $1.57Exp: 2031-01-27Common Stock (60,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-11-1365,0000 total
    Exercise: $19.86Exp: 2032-01-27Common Stock (65,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2024-11-13+68,00068,000 total
    Exercise: $1.57Exp: 2033-01-30Common Stock (68,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-11-1390,0000 total
    Exercise: $24.75Exp: 2034-01-30Common Stock (90,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2024-11-13+90,00090,000 total
    Exercise: $1.57Exp: 2034-01-30Common Stock (90,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2024-11-13+65,00065,000 total
    Exercise: $1.57Exp: 2032-01-27Common Stock (65,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-11-1368,0000 total
    Exercise: $29.05Exp: 2033-01-30Common Stock (68,000 underlying)
Footnotes (9)
  • [F1]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 2, 2019 and is fully vested.
  • [F2]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 28, 2021.
  • [F3]1/48th of the shares subject to the option vested or shall vest on each monthly anniversary of the vesting commencement date of January 1, 2021.
  • [F4]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 28, 2022.
  • [F5]1/48th of the shares subject to the option vested or shall vest on each monthly anniversary of the vesting commencement date of January 1, 2022.
  • [F6]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 31, 2023.
  • [F7]1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of January 1, 2023.
  • [F8]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 31, 2024.
  • [F9]1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of January 1, 2024.

Documents

1 file
  • 4
    form4-11152024_081114.xmlPrimary